Vyome Biosciences, a pharmaceutical company developing medicines for skin diseases affected by Antibiotic -resistance, has appointed Charles G. Chavdarian Ph.D. senior vice president of product development and regulatory CMC (chemistry, manufacturing and controls).
Dr. Chavdarian comes with more than 30 years of pharmaceutical R&D, commercial, and regulatory affairs experience. In his new role, he will Lead product development strategies and oversee the regulatory process related to CMC of Vyome’s investigational products.
“Charles possesses a wealth of knowledge and experience in product development through all stages, as well as a strong understanding of regulatory affairs related to CMC,” said Venkateswarlu Nelabhotla, co-founder and chief executive officer of Vyome. “He will be a valuable addition to our team as we further develop our dermatology pipeline.”
Prior to joining Vyome, Dr. Chavdarian served as the executive director of analytical sciences & regulatory CMC at Dow Pharmaceutical Sciences. Inc.
